Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | F13A1 | P00488 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661655 | 1.00 | MAPT (0.55) | MAPTRXFP1TBXAS1TSHRF13A1 | |
| SCHEMBL1471746 | 1.00 | MAPT (0.55) | MAPTRXFP1TBXAS1TSHRF13A1 | |
| SCHEMBL2932213 | 1.00 | MAPT (0.55) | MAPTRXFP1TBXAS1TSHRF13A1 | |
| SCHEMBL27608146 | 0.98 | MAPT (0.52) | MAPTRXFP1TBXAS1TSHRF13A1 | |
| SCHEMBL736098 | 0.93 | HDAC3 (0.52) | MAPTRXFP1TBXAS1TSHRHDAC3 | |
| SCHEMBL28269903 | 0.91 | EPHX2 (0.50) | MAPTRXFP1TSHRLMNA | |
| SCHEMBL9680709 | 0.89 | MAPT (0.45) | MAPTRXFP1TBXAS1TSHRF13A1 | |
| SCHEMBL735832 | 0.85 | TSHR (0.53) | TSHRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8955030 | 0.82 | GPR84 (0.44) | — | |
| SCHEMBL4170437 | 0.82 | ALDH1A1 (0.40) | MAPTRXFP1TBXAS1TSHRHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624208-B | Fluorescent probe for targeting liver cancer cells and preparation method and application thereof | 临沂大学 | 2024-07-12 | — | — | CN | claimed |
| CN-117624208-A | Fluorescent probe for targeting liver cancer cells and preparation method and application thereof | 临沂大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117624208-B | Fluorescent probe for targeting liver cancer cells and preparation method and application thereof | 临沂大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117624208-A | Fluorescent probe for targeting liver cancer cells and preparation method and application thereof | 临沂大学 | 2024-03-01 | — | — | CN | disclosed |
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190069527-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2019-03-07 | — | — | US | disclosed |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | CLEVELAND CLINIC FOUND (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180160660-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2018-06-14 | — | — | US | disclosed |
| US-9981018-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170176470-A1 | DETECTION OF CARBOXYALKYLPYRROLE OR PENTYLPYRROLE ETHANOLAMINE PHOSPHOLIPIDS | UNIV CASE WESTERN RESERVE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170105394-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2017-04-20 | — | — | US | disclosed |
| WO-2008089485-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089487-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080160505-A1 | DIAGNOSTIC METHODS FOR AGE RELATED MACULAR DEGENERATION | THE CLEVELAND CLINIC FOUNDATION | 2008-07-03 | — | — | US | disclosed |
| US-7341839-B2 | Diagnostic methods for age related macular degeneration | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008013797-A2 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007127151-A2 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070072241-A1 | diagnosing age-related macular degeneration comprising determining the level of anti-2-( omega -carboxyethyl) pyrrole (CEP) antibodies in a bodily fluid obtained from the test subject | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-7172874-B2 | Diagnostic methods for age related macular degeneration | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040265924-A1 | Diagnostic methods for age related macular degeneration | THE CLEVELAND CLINIC FOUNDATION | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | TLR2, TLR3, TLR1 | MAPT 4050/4885RXFP1 836/4885TBXAS1 3654/4885 |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | TLR2, TLR3, TLR1 | MAPT 4050/4885RXFP1 836/4885TBXAS1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.